<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="54399"><DrugName>EPI-A0001</DrugName><DrugSynonyms><Name><Value>coenzyme Q10 analog (Friedreich's ataxia), Edison Pharmaceuticals</Value></Name><Name><Value>coenzyme Q10 analog (Friedreich's ataxia), Penwest Pharmaceuticals</Value></Name><Name><Value>alpha-tocopherylquinone</Value></Name><Name><Value>A-0001, Penwest Pharmaceuticals</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>alpha-tocopherolquinone</Value></Name><Name><Value>EPI-A0001</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1017672">BioElectron Technology Corp</CompanyOriginator><CompaniesSecondary><Company id="1017672">BioElectron Technology Corp</Company><Company id="25180">Penwest Pharmaceuticals Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="54399" type="Drug"><TargetEntity id="296403" type="siDrug">alpha-Tocopherolquinone</TargetEntity><TargetEntity id="411501" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1017672" type="Company"><TargetEntity id="5000450679" type="organizationId">Bioelectron Technology Corp</TargetEntity></SourceEntity><SourceEntity id="25180" type="Company"><TargetEntity id="4295914518" type="organizationId">Penwest Pharmaceuticals Co</TargetEntity></SourceEntity><SourceEntity id="2540" type="ciIndication"><TargetEntity id="D028361" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="2543" type="ciIndication"><TargetEntity id="E88.41" type="ICD10"></TargetEntity><TargetEntity id="10053872" type="MEDDRA"></TargetEntity><TargetEntity id="D017241" type="MeSH"></TargetEntity><TargetEntity id="550" type="ORPHANET"></TargetEntity><TargetEntity id="-1865696555" type="omicsDisease"></TargetEntity><TargetEntity id="1833" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2974" type="ciIndication"><TargetEntity id="10017374" type="MEDDRA"></TargetEntity><TargetEntity id="D005621" type="MeSH"></TargetEntity><TargetEntity id="95" type="ORPHANET"></TargetEntity><TargetEntity id="-1147034178" type="omicsDisease"></TargetEntity><TargetEntity id="86" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="2540">Mitochondrial disease</Indication><Indication id="2543">MELAS syndrome</Indication><Indication id="2974">Friedreich ataxia</Indication></IndicationsSecondary><ActionsSecondary><Action id="1732">Energy metabolism modulator</Action><Action id="2939">CNS modulator</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-21T11:15:48.000Z</LastModificationDate><ChangeDateLast>2014-12-06T00:00:00.000Z</ChangeDateLast><AddedDate>2005-11-09T11:36:33.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1017672" linkType="Company"&gt;Edison Pharmaceuticals&lt;/ulink&gt; was developing  EPI-A0001 (A-0001; alpha-tocopherolquinone), a coenzyme Q10 analog and energy metabolism modulator, as an oral capsule formulation for the potential treatment of mitochondrial diseases [&lt;ulink linkID="633302" linkType="Reference"&gt;633302&lt;/ulink&gt;], [&lt;ulink linkID="813841" linkType="Reference"&gt;813841&lt;/ulink&gt;], [&lt;ulink linkID="924992" linkType="Reference"&gt;924992&lt;/ulink&gt;]. In December 2009, a phase IIa study in patients with Friedreich's ataxia was initiated in the US [&lt;ulink linkID="1066328" linkType="Reference"&gt;1066328&lt;/ulink&gt;]; in June 2011, preliminary results showed the trial had failed to meet its primary endpoint  [&lt;ulink linkID="1199277" linkType="Reference"&gt;1199277&lt;/ulink&gt;]; in February 2013, development was ongoing [&lt;ulink linkID="1383718" linkType="Reference"&gt;1383718&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="25180" linkType="Company"&gt;Penwest Pharmaceuticals&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="26192" linkType="Company"&gt;Endo Pharmaceuticals&lt;/ulink&gt;) was previously developing the drug under license from Edison for the potential treatment of mitochondrial diseases, including Friedreich's ataxia and  mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome [&lt;ulink linkID="633302" linkType="Reference"&gt;633302&lt;/ulink&gt;], [&lt;ulink linkID="813841" linkType="Reference"&gt;813841&lt;/ulink&gt;], [&lt;ulink linkID="924992" linkType="Reference"&gt;924992&lt;/ulink&gt;]. In February 2010, a phase IIa trial in patients with MELAS syndrome was initiated in the UK; data were expected  in the third quarter of 2010 [&lt;ulink linkID="1074052" linkType="Reference"&gt;1074052&lt;/ulink&gt;]. In April 2010, the company expected to decide whether or not to proceed with development of the drug by the third quarter of 2010 [&lt;ulink linkID="1093314" linkType="Reference"&gt;1093314&lt;/ulink&gt;]. In March 2010,  Penwest planned to  seek to outlicense the drug for development  after the phase IIa trials had been completed [&lt;ulink linkID="1079364" linkType="Reference"&gt;1079364&lt;/ulink&gt;]. However, by June 2011, Penwest was presumed to have returned all rights to Edison [&lt;ulink linkID="1199277" linkType="Reference"&gt;1199277&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2006, the drug received Orphan Drug designation from the FDA [&lt;ulink linkID="659841" linkType="Reference"&gt;659841&lt;/ulink&gt;].  In March 2010, the FDA awarded the drug Fast Track status for Friedreich's ataxia [&lt;ulink linkID="1096060" linkType="Reference"&gt;1096060&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In July 2009, a phase IIa trial in patients with  MELAS syndrome was to begin in the fourth quarter of 2009.  Patients  would receive twice daily oral dosing. At that time results were expected in the first half of 2010 [&lt;ulink linkID="1026083" linkType="Reference"&gt;1026083&lt;/ulink&gt;], [&lt;ulink linkID="1032336" linkType="Reference"&gt;1032336&lt;/ulink&gt;]. In February 2010, a double-blind, randomized, placebo-controlled  phase IIa trial was initiated in the UK in patients (expected n = 30) with the A3243G mitochondrial DNA point mutation associated with MELAS syndrome. The primary endpoint was to assess  the effect of  EPI-A0001 using metabolic imaging, functional assessments, biochemical measures and patient/clinician-rated scales.  Patients would receive the drug for 28 days and data from the trial were expected in the third quarter of 2010 [&lt;ulink linkID="1074052" linkType="Reference"&gt;1074052&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a phase IIa trial was expected to begin in the fourth quarter of 2009, in patients with Friedreich's ataxia. Patients  would receive twice daily oral dosing. At that time results were expected in the first half of 2010 [&lt;ulink linkID="1026083" linkType="Reference"&gt;1026083&lt;/ulink&gt;].  In December 2009, a randomized, double-blind, placebo-controlled, phase IIa study (&lt;ulink linkID="62857" linkType="Protocol"&gt;NCT01035671&lt;/ulink&gt;; FRD02) was initiated in patients with Friedreich's ataxia (expected  n = 42) in the US, to assess the safety and efficacy of EPI-A0001. The study was expected to be complete by June 2010 [&lt;ulink linkID="1066328" linkType="Reference"&gt;1066328&lt;/ulink&gt;].  In January 2010, screening for the trial was ongoing. Patients would receive placebo or a high or low dose of EPI-A0001 for 28 days. At that time, data were expected in the third quarter of 2010 [&lt;ulink linkID="1067792" linkType="Reference"&gt;1067792&lt;/ulink&gt;]. In June 2011, preliminary results showed the trial had failed to meet its primary endpoint of significant improvement in glucose disposition index. Data did  show however, that there was a significant improvement in neurological function in both dose cohorts, as measured by the Friedreich's Ataxia Rating Scale. There were no differences in drug-related adverse events between placebo and drug groups   [&lt;ulink linkID="1199277" linkType="Reference"&gt;1199277&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In July 2008, the company was planning a phase Ib trial  [&lt;ulink linkID="924992" linkType="Reference"&gt;924992&lt;/ulink&gt;]. In November 2008, the company disclosed that the trial would be a multiple-ascending-dose study, assessing the safety and tolerability of the drug in healthy subjects [&lt;ulink linkID="959162" linkType="Reference"&gt;959162&lt;/ulink&gt;]. In February 2009, the 30-subject, single-blind, placebo-controlled trial began. The trial would establish the pharmacokinetic profile following repeated dosing [&lt;ulink linkID="986796" linkType="Reference"&gt;986796&lt;/ulink&gt;]. In July 2009, results were announced, showing the drug to be well tolerated. There were no serious adverse events and a maximum tolerated dose was determined. A dose-dependent increase in exposure was observed which approached steady state within 1 to 4 days after repeat-dosing. Approximately 40 healthy male and female subjects took part in the trial for up to 14 days [&lt;ulink linkID="1026083" linkType="Reference"&gt;1026083&lt;/ulink&gt;]. By August 2009, the trial had been completed [&lt;ulink linkID="1032336" linkType="Reference"&gt;1032336&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, the company began a placebo-controlled, single ascending dose, phase Ia study in healthy subjects (expected n=60). The trial would evaluate the safety and tolerability of the drug, and determine the MTD  [&lt;ulink linkID="924992" linkType="Reference"&gt;924992&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By July 2009, the drug had been shown to improve mitochondrial function in-vitro [&lt;ulink linkID="1026083" linkType="Reference"&gt;1026083&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2009, Penwest began long-term toxicology animal studies [&lt;ulink linkID="986796" linkType="Reference"&gt;986796&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2007, Penwest licensed exclusive worldwide development and marketing  rights to EPI-A0001 from Edison [&lt;ulink linkID="813841" linkType="Reference"&gt;813841&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2005, Edison raised $2.8 million from a series A preferred stock offering. The funds would support the clinical development of EPI-A0001 [&lt;ulink linkID="637621" linkType="Reference"&gt;637621&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2005, the Friedreich's Ataxia Research Alliance  awarded Edison  a $3 million grant to further the development of EPI-A0001 [&lt;ulink linkID="633302" linkType="Reference"&gt;633302&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25180">Penwest Pharmaceuticals Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2543">MELAS syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-10T00:00:00.000Z</StatusDate><Source id="1199277" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25180">Penwest Pharmaceuticals Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2540">Mitochondrial disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-10T00:00:00.000Z</StatusDate><Source id="1199277" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25180">Penwest Pharmaceuticals Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2974">Friedreich ataxia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-10T00:00:00.000Z</StatusDate><Source id="1199277" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017672">BioElectron Technology Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2974">Friedreich ataxia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1017672">BioElectron Technology Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2974">Friedreich ataxia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-10T00:00:00.000Z</StatusDate><Source id="1199277" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25180">Penwest Pharmaceuticals Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2540">Mitochondrial disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-17T00:00:00.000Z</StatusDate><Source id="813841" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017672">BioElectron Technology Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="2540">Mitochondrial disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-17T00:00:00.000Z</StatusDate><Source id="813841" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25180">Penwest Pharmaceuticals Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2540">Mitochondrial disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-14T00:00:00.000Z</StatusDate><Source id="924992" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25180">Penwest Pharmaceuticals Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2543">MELAS syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-09T00:00:00.000Z</StatusDate><Source id="1074052" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25180">Penwest Pharmaceuticals Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2974">Friedreich ataxia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1066328" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017672">BioElectron Technology Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2540">Mitochondrial disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-11-09T00:00:00.000Z</StatusDate><Source id="633302" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="25180">Penwest Pharmaceuticals Co</OwnerCompany><Country id="US">US</Country><Indication id="2974">Friedreich ataxia</Indication><AwardedIndication>Treatment of Friedreich's ataxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-05-03T00:00:00.000Z</MileStoneDate><Source id="1096060" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1017672">BioElectron Technology Corp</OwnerCompany><Country id="US">US</Country><Indication id="2540">Mitochondrial disease</Indication><AwardedIndication>Treatment of inherited mitochondrial respiratory chain diseases.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-21T00:00:00.000Z</MileStoneDate><Source id="659841" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25180">Penwest Pharmaceuticals Co</OwnerCompany><Country id="US">US</Country><Indication id="2540">Mitochondrial disease</Indication><AwardedIndication>Treatment of inherited mitochondrial respiratory chain diseases</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-28T00:00:00.000Z</MileStoneDate><Source id="659841" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1017672">BioElectron Technology Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1053730">Friedreich's Ataxia Research Alliance</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1089706">Endo International plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC1=C(C(=O)C(=C(C1=O)C)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O)C</Smiles></StructureSmiles><Deals><Deal id="109925" title="Penwest to develop Edison’s EPI-A0001"></Deal><Deal id="125813" title="Friedreich's Ataxia Research Alliance to fund development of Edison's EPI-A0001"></Deal></Deals><PatentFamilies><PatentFamily id="1337883" number="WO-2010030607" title="Treatment of pervasive developmental disorders with redox-active therapeutics"></PatentFamily><PatentFamily id="1383817" number="WO-2010045220" title="Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells"></PatentFamily><PatentFamily id="1393105" number="WO-2006130775" title="Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers"></PatentFamily><PatentFamily id="152333" number="WO-2012009271" title="Methods of providing anticoagulation effects in subjects"></PatentFamily><PatentFamily id="1627130" number="WO-2011112679" title="Synthesis of α-tocopherolquinone derivatives, and methods of using the same"></PatentFamily><PatentFamily id="2002119" number="WO-2010151348" title="Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts"></PatentFamily><PatentFamily id="2008231" number="WO-2011025785" title="Methods for the prevention and treatment of cerebral ischemia"></PatentFamily><PatentFamily id="2194034" number="WO-2009111543" title="Treatment of hearing and balance impairments with redox-active therapeutics"></PatentFamily><PatentFamily id="2428068" number="WO-2012170773" title="Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones"></PatentFamily><PatentFamily id="4228786" number="WO-2018191732" title="Methods and compositions for treatment of inflammation and oxidative stress"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioElectron Technology Corp" id="1017672"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ampere Life Sciences Inc" id="1061441"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>